A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy

International Journal of Gynecological Cancer

Volumn 18, Issue 1, 2008, Pages 51-58

  Comander, A H ^a,b   Cannistra, S A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Maintenance chemotherapy; Ovarian cancer; Topotecan

Indexed keywords

ALKALINE PHOSPHATASE; CREATININE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATINUM; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER PATIENT; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; LIVER FAILURE; LOW DRUG DOSE; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOSARCOMA; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; REMISSION INDUCTION; TOPOTECAN;

EID: 38049086811     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00978.x     Document Type: Article

References (18)

1. Cannistra SA. Cancer of the ovary. N Engl J Med 2004 351 : 2519 29.
2. Gadducci A, Cosio S, Conte PF, Genazzani AR. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol 2005 55 : 153 66.
3. ten Bokkel HW, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997 15 : 2183 93.
4. Gore M, ten Bokkel HW, Carmichael J et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 2001 19 : 1893 900.
5. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001 19 : 3312 22.
6. De Placido S, Scambia G, Di Vagno G et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: multicenter Italian trials in ovarian cancer (MITO-1) randomized study. J Clin Oncol 2004 22 : 2635 42.
7. Pfisterer J, Weber B, du Bois A et al. Paclitaxel/carboplatin vs. paclitaxel/carboplatin followed by topotecan in first-line treatment of advanced ovarian cancer. Mature results of a gynecologic cancer intergroup phase III trial of the AGO OVAR and GINECO [abstract]. ASCO 2005 23 : 456 Abstracts 2005.
8. Hoskins P, Eisenhauer E, Beare S et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998 16 : 2233 7.
9. Homesley HD, Hall DJ, Martin DA et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 2001 83 : 394 9.
10. Clarke-Pearson DL, Van Le L, Iveson T et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 2001 19 : 3967 75.
11. Gore M, Oza A, Rustin G et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 2002 38 : 57 63.
12. Creemers GJ, Gerrits CJ, Eckardt JR et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 1997 15 : 1087 93.
13. Jelliffe RW. Letter: creatinine clearance: bedside estimate. Ann Intern Med 1973 79 : 604 5.
14. Gerrits CJ, Burris H, Schellens JH et al. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. Clin Cancer Res 1998 4 : 1153 8.
15. Rothenberg ML, Liu PY, Wilczynski S et al. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). Gynecol Oncol 2001 82 : 317 22.
16. Bolis G, Danese S, Tateo S et al. Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. Int J Gynecol Cancer 2006 16 (Suppl. 1 74 8.
17. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003 21 : 2460 5.
18. Markman M, PL, Wilczynski S, Monk B, Copeland L, Alberts D. Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG9701/GOG178: 12 versus (v) 3 cycles (C) of monthly single-agent paclitaxel (PAC) following attainment of a clinically-defined complete response (CR) to platinum (PLAT)/PAC. Journal of Clinical Oncology 2006 ASCO Annual Meeting Proceedings Part I 2006 24 (Suppl 2575.